The takeaway
LB Pharmaceuticals Inc Common Stock shows a pronounced seasonal pattern over 1 years of data — strongest in December (+27.7%) and softest in September (−8.7%).
Right now
Not enough July history yet to summarize.
The full picture
LB Pharmaceuticals Inc Common Stock's most dependable month has been December, higher in 1 of 1 years; September has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | — | — | — | — | — | — | — | — | ||||
| Median return % | — | — | — | — | — | — | — | — | ||||
| 2025 | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in December (+26.7 pts); it has trailed the market most in September (−8.6 pts).
“vs S&P” is LB Pharmaceuticals Inc Common Stock’s average for a month minus the S&P 500’s average for that same month — isolating LB Pharmaceuticals Inc Common Stock’s own seasonal edge from broad market drift.
Reality check
Not enough recent December history to say whether the pattern still holds.
Figures are the typical (median) December return and how often it rose — the last 1 years versus the last 1(the heatmap’s default window). This verdict stays anchored to that 1-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
This is a stock you can almost set a calendar by, and December is the anchor — it has closed higher in all 1 Decembers, the steadiest beat on its year.
The strength looks broad-based rather than freakish: its average (+27.7%) and median (+27.7%) sit close together, so no single blow-out year is flattering the figure. No month is steadier: December's returns vary by just 0.0% year to year, and even its worst December in 1 years lost only 27.7% — the gentlest downside anywhere on its calendar. Better still, that strength is the stock's own and not just a buoyant market — December has outpaced the S&P 500 by +26.7 points on average. Few peers keep such company in December — the typical stock clears it just 58% of the time.
December anchors a run, too: the October-through-December window has been the stock's reliable season. At the other end of the calendar, September has been the soft spot — the only month to average an outright loss (−8.7%), and the edge isn't year-round — the stock has trailed the S&P 500 in September.
For a stock this dependable in December, the sharper question is the rest of the year — outside its strong stretch, the calendar gives far less to lean on. With a short 1-year record, the signal is best held loosely.
Short answers on the stock's best month (December), its worst (September), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2025 its best month (December, +27.7%) has run well ahead of its worst (September, −8.7%) — the heatmap above shows how steady that gap has been year to year.
December has been the strongest, averaging +27.7% and closing higher in its one year on record since 2025.
It's the weakest, averaging −8.7% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade